This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Discovery Corporation Appoints Maher Albitar M.D., Former Medical Director Of Hematology And Oncology And Chief Of Research And Development At Quest Diagnostics, Chief Medical Officer

Health Discovery Corporation (OTCBB: HDVY) (HDC) announced today the appointment of Maher Albitar, M.D., a world renowned cancer scientist and inventor, to the position of Chief Medical Officer. Until recently, Dr. Albitar was the Medical Director of Hematology and Oncology and Chief of Research and Development at Quest Diagnostics Nichols Institute (NYSE: DGX), San Juan Capistrano, Calif. Prior to Quest Diagnostics, Dr. Albitar was a tenured full professor at the M.D. Anderson Cancer Center and the University of Texas, where he served as chief of the hematopathology of the leukemia section with joint appointment in the clinical leukemia department.

“Dr. Albitar is a globally respected cancer researcher with the unique combination of both academic and commercial experience having held high level appointments at Quest Diagnostics, the largest commercial clinical laboratory in the world, as well as M.D. Anderson Cancer Center, voted the top hospital in the nation for cancer care, according to the U.S. News & World Report annual 'America's Best Hospitals,'” said Stephen D. Barnhill, M.D., Chairman and CEO at Health Discovery Corporation. “We’re thrilled to have Dr. Albitar join our team and lead our molecular diagnostic and medical imaging discovery, development and commercialization program.”

“For a long-time, I’ve admired Dr. Barnhill and his cutting-edge work in addressing the urgent need for effective cancer diagnostic test development,” said Dr. Albitar. “I am very impressed with HDC’s progress in prostate cancer, breast cancer, colon cancer, leukemia, pancreatic cancer and melanoma, and I am looking forward to working closely with the distinguished team at HDC to increase the pipeline of cancer diagnostic and prognostic tests and prepare these tests for commercialization.”

Dr. Albitar will immediately help position the Company to expand its pipeline of molecular diagnostic and medical imaging tests for cancer using the Company’s patented Support Vector Machine technology. The Company holds 43 issued patents and 32 pending patents related to its SVM and SVM-RFE development tools.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
HDVY $0.02 -6.25%
AAPL $132.65 1.82%
FB $81.91 0.47%
GOOG $555.39 -1.70%
TSLA $231.55 6.01%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs